Actionable insights straight to your inbox

Equities logo

Navitor Pharmaceuticals, Inc. Files SEC Form D, Notice of Exempt Offering of Securities [Amend] (Jun. 26, 2014)

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission

By a News Reporter-Staff News Editor at Pharma Business Week — According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Navitor Pharmaceuticals, Inc. (Form D) was posted on June 26, 2014.
There was one document filed with this form. The SEC file number is 0001588059-14-000002.
The contact information for this company is 700 MAIN STREET, CAMBRIDGE MA 02139, 781-538-6113.
Our editors provided additional information about Form D: Companies selling securities in reliance on a Regulation D exemption or a Section 4(6) exemption from the registration provisions of the ’33 Act must file a Form D as notice of such a sale. The form must be filed no later than 15 days after the first sale of securities. For additional information on Regulation D and Section 4(6) offerings, ask for a copy of the Regulation and the pamphlet entitled: “Q & A: Small Business and the SEC” from the Commission’s Publications Unit or see the Small Business Section of the Commission’s Web Site.
A U.S. Securities and Exchange Commission filing is a formal document or financial statement submitted to the SEC by publicly-traded companies.
For additional information on this SEC filing see: http://www.sec.gov/Archives/edgar/data/1588059/0001588059-14-000002-index.html.
Keywords for this news article include: Navitor Pharmaceuticals Inc.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

Why distillate crack spreads will likely experience more volatility.